Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Melanoma Approvals Break New Ground In Immunotherapy

Executive Summary

First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.


Related Content

Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race
Does Imlygic Make The Case For FDA Oncology Center Of Excellence?
Merck Points To Keytruda, Zepatier Promise Coming Off Lackluster Quarter
Bristol Cements Lead In Immunotherapy
Bristol Offers Yervoy For Free In New Early Melanoma Indication
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
Creative Drug Pricing Hindered By Medicaid Best Price, Stakeholders Say
Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing
Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal


Related Companies